To buy shares in Entrada Therapeutics Inc. you will need a US based stock trading platform like Interactive Brokers, eToro or Moomoo where it currently costs $8.82 to buy one share in Entrada Therapeutics Inc. (as of 16:00 12-May-2025). Which is a change of $0.44 or 5.25% from the last closing price of $8.38.
How To Buy Entrada Therapeutics Inc. Stock
It may seem complicated to buy stock for the first time, but it’s actually very easy. Follow these simple steps to buy shares in Entrada Therapeutics Inc.:
- Pick a stock broker (jump down to compare the best brokers for buying Entrada Therapeutics Inc. stock)
- Deposit funds (bank transfer, ACH, wire transfer, or card)
- Search for the stock symbol: (NASDAQ:TRDA)
- Choose the number of shares you want to buy (1 share currently costs $8.82)
- Click buy (you can either trade immediately at “market” or set a “limit” to buy the stock cheaper if you think the price will go down)
- Track the performance of your Entrada Therapeutics Inc. stock in your account (this will show your profit and loss)
Entrada Therapeutics Inc. Share Price (TRDA) Quote & Overview
This section shows the most important aspects of the current Entrada Therapeutics Inc. TRDA:US share price including price, change, bid/offer spread and volume.
- Entrada Therapeutics Inc. is currently worth $334,749,064 based on the last closing price of $8.38 with 145,355 shares traded.
- The most recent Entrada Therapeutics Inc. daily high has been $9.09 and daily low $8.52.
- The Entrada Therapeutics Inc. stock price 52 week high has been $21.79 and the 52 week low $7.1.
Compare Brokers For Buying Entrada Therapeutics Inc. Stock
It’s usually commission-free to buy US stocks as American stock brokers make their money from payment for order flow. However, there can sometimes be additional charges for buying stocks in an IRA, where your contributions are tax-deductible.
| US Stock Broker | US Stocks Available | Dealing Commission | Margin Rates | Customer Reviews | More Info |
|---|---|---|---|---|---|
 | 17,913 | 0.003% | 5.33% – 6.33% | (Based on 934 reviews)
| Visit Broker Your capital is at risk |
 | 6,000+ | 0% | 0% | (Based on 144 reviews)
| Visit Broker Your capital is at risk |
 | 5,000+ | 0% | 8% – 11% | (Based on 0 reviews)
| Read Reviews |
 | 4,000+ | 0% | 10.2% – 13.2% | (Based on 1 reviews)
| Read Reviews |
 | 4,000+ | 0% | 8.575% – 13.075% | (Based on 22 reviews)
| Read Reviews |
 | 5,000+ | 0% | 8% (Flat) | (Based on 23 reviews)
| Read Reviews |
 | 7,000+ | 0% | 8.5% – 12.075% | (Based on 0 reviews)
| Read Reviews |
 | 5,000+ | 0% | 9.49% (Flat) | (Based on 0 reviews)
| Read Reviews |
Is Now A Good Time To Buy Entrada Therapeutics Inc. Stock?
For expert analysis join Good Money Guide Premium.
- Entrada Therapeutics Inc.’s EPS (earnings per share) are 1.68. A high EPS indicates strong profitability but may already be priced in, while a low EPS could signal weak earnings or a turnaround opportunity, requiring industry comparison.
- Entrada Therapeutics Inc.’s PE (price earnings ratio) is 5.24. A low PE ratio may suggest undervaluation but could also indicate slow growth or risk, whereas a high PE ratio reflects high growth expectations but may signal overvaluation, necessitating a check on earnings sustainability.
The below Entrada Therapeutics Inc. share price analysis and market data includes key financials, earnings estimates, peer performance, dividends, news and a company profile that will give you an indication as to whether this stock is a buy, sell or hold.
Entrada Therapeutics Inc. (TRDA) Analysis
This section shows analysis for Entrada Therapeutics Inc. TRDA:US. It shows analyst rating, recommnedations and history, as well industry ranking comparison.
Entrada Therapeutics Inc. (TRDA) Earnings Estimates & Forecasts
This section shows how analysts expect the Entrada Therapeutics Inc. TRDA:US share price to perform in the future based on their earnings reports and estimates. It gives an overview of future short, long and medium term price targets as well as previous earnings reports.
Entrada Therapeutics Inc. (TRDA) Company Financials
This section shows current and previous Entrada Therapeutics Inc. TRDA:US profit and loss information like revenue, income, expenses and earnings per share.
Entrada Therapeutics Inc. (TRDA) Financial Summary
This section allows you to compare Entrada Therapeutics Inc. TRDA:US revenue, net income, cash flow statement and balance sheet against previous years. This can give you a good indication of how well a company is performing.
Entrada Therapeutics Inc. (TRDA) Share Price History
This section provides a visual and table view of the historic Entrada Therapeutics Inc. TRDA:US share price including volume and VWAP which can be adjusted for splits and dividends.
Entrada Therapeutics Inc. (TRDA) Interactive Chart
This section allows you to compare Entrada Therapeutics Inc. TRDA:US share price chart against other stocks as well as overlay key events like dividends, earnings and splits.
Entrada Therapeutics Inc. (TRDA) Dividends
This section analyses the historic and upcoming Entrada Therapeutics Inc. TRDA:US dividend amounts, dates and yields. It provides a good indication of potential future and past profitability.
Entrada Therapeutics Inc. (TRDA) Corporate Events
This section shows key dates in Entrada Therapeutics Inc. TRDA:US corporate calendar like company announcements, earnings releases, stock splits, and fundamental data chances like EPS updates.
Entrada Therapeutics Inc. (TRDA) Share Price Performance
This section shows key Entrada Therapeutics Inc. TRDA:US share price levels like recent highs and lows, plus gives you tools to see average day traded volumes and institutional share holders major buys and sells.
Entrada Therapeutics Inc. (TRDA) Share Price News
This section shows new stories that are relevant to and may effect or explain changes in Entrada Therapeutics Inc. TRDA:US share price.
Entrada Therapeutics Inc. (TRDA) Company Profile
This section provides corporate information on Entrada Therapeutics Inc. TRDA:US, including what they do, their contact details, their CEO and auditor as well as in what sectors their shares trade.
